Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. - Wikidata - wikimedia - TriplyDB

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q33587034

about

A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.Adoptive T-Cell Therapy for Solid Tumors.Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.

P2860

Q26777111-5B4BCAD0-2FA7-48A0-B1BB-C599EFE9A491 Q34240799-57473B4A-FE89-4A7F-A743-E65B9F2219E7 Q38656009-6D45CD84-7388-4AA5-8824-EE500BA78C05 Q38754498-F2338AAB-CF5A-426A-B2E8-C1B4499C15A7 Q38822723-5C721747-467F-469C-B228-9B1EE7A5593B Q39790928-27B6BA26-C862-416C-9CA0-D7AC58B0FB29 Q41625041-9E558151-4C05-44A8-B15E-8EFCDFE99A45 Q49477144-AE1A5FEE-CADF-4607-98C5-57E5DCA708EC

P2860

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q33587034

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Elimination of progressive mam ...... gen receptor-modified T cells.

@ast

Elimination of progressive mam ...... gen receptor-modified T cells.

@en

Elimination of progressive mam ...... gen receptor-modified T cells.

@nl

type

label

Elimination of progressive mam ...... gen receptor-modified T cells.

@ast

Elimination of progressive mam ...... gen receptor-modified T cells.

@en

Elimination of progressive mam ...... gen receptor-modified T cells.

@nl

prefLabel

Elimination of progressive mam ...... gen receptor-modified T cells.

@ast

Elimination of progressive mam ...... gen receptor-modified T cells.

@en

Elimination of progressive mam ...... gen receptor-modified T cells.

@nl

P1433

Q33587034-10DC64C5-DA42-4263-8BAC-D10C4F77FD8E

P1476

Q33587034-A96B80DA-05B7-4890-BF5B-89AC385C6385

P2093

Q33587034-17E82C63-908C-4204-8288-9C9F0E6D853D

Q33587034-8F6D7481-8A2C-4330-898C-9070E3386035

Q33587034-F844DBD7-7CD6-423E-A14B-451FB2EE0517

P2860

Q33587034-01A5E27E-D59C-464D-A348-43436F3452B7

Q33587034-0812AB38-7A0F-4FC3-83B9-D9344034DEEA

Q33587034-0E665D3C-32B8-466C-87E8-CF1EF53C133B

Q33587034-14E1F504-FD04-47C7-BE0E-691B3E32EF19

Q33587034-18C4823A-1D5D-47EA-B6E2-F0D36BD8DB23

Q33587034-1BDFF33A-02C8-44B5-BD0B-7C2E4B4CF5AE

Q33587034-1C8164D3-D69E-43E6-83CC-30E8205F900A

Q33587034-21839737-447D-461D-AC59-AC41BD9A5648

Q33587034-24E34478-16A8-470F-9BE3-7678CD99883A

Q33587034-310986B2-32FD-4C58-9F81-0A3F131F0288

P304

Q33587034-6400F595-808D-42F6-B924-3EC9863CDC1A

P31

Q33587034-6E043B9E-444F-4066-8927-F6AA3CD64B7A

P356

Q33587034-E89A92D5-00B7-48F7-920E-90978041EF43

P433

Q33587034-F1309589-5DA3-4F62-8E63-246FFE71734B

P478

Q33587034-FDDFB2E7-E076-431A-BC33-CC6105C13C8F

P577

Q33587034-352362E7-2B1B-4E0B-88FD-ECA809E58D46

P698

Q33587034-6254FEEB-DE80-4079-B5D0-63EF20C2EAF5

P932

Q33587034-49192C3B-54C3-4DA4-9CBD-047A111B7FE4

P356

P1433

Molecular Therapy

P1476

Elimination of progressive mam ...... gen receptor-modified T cells.

@en

P2093

Anat Globerson-Levin

http://www.w3.org/2001/XMLSchema#string

Tova Waks

http://www.w3.org/2001/XMLSchema#string

Zelig Eshhar

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

P304

1029-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2014.28

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24572294

http://www.w3.org/2001/XMLSchema#string

P932

4015244

http://www.w3.org/2001/XMLSchema#string